Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATALINA-2: TORL-1-23 in Advanced Platinum-Resistant Ovarian Cancer
2024-517190-24-00Phase 2Suspended
- Sponsor
- TORL BioTherapeutics
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of ixotatug vedotin in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by TORL BioTherapeutics. Primary endpoint: Objective Response Rate by BICR (RECIST v1.1). Started Jul 2025; status: suspended.
02
Drugs
ixotatug vedotin
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2024-517190-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517190-24-00.